3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Colorectal Neoplasms
30
Carcinoma, Hepatocellular
13
Rectal Neoplasms
5
Sarcoma, Ewing
4
Osteosarcoma
4
Gastrointestinal Stromal Tumors
4
Colonic Neoplasms
4
Parkinson Disease 4, Autosomal Dominant Lewy Body
3
Neoplasm Metastasis
3
Glioblastoma
3
Sarcoma
2
Neoplasms
2
Lung Neoplasms
2
Leukemia, Myeloid, Acute
2
Esophageal Neoplasms
2
Chondrosarcoma
2
Bone Neoplasms
2
Uterine Cervical Neoplasms
1
Thyroid Neoplasms
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Spinocerebellar Degenerations
1
Solid Malignant Tumors
1
Small Cell Lung Carcinoma
1
Recurrence
1
Piebaldism
1
Patient Compliance
1
Pathologic Complete Response
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Interventions
Nivolumab
3
capivasertib
2
Gemcitabine
2
Cisplatin
2
tivozanib
1
regorafenib
1
niraparib
1
neratinib
1
lutetium Lu 177 dotatate
1
fludarabine phosphate
1
fludarabine
1
encorafenib
1
durvalumab
1
copanlisib
1
cemiplimab
1
axicabtagene ciloleucel
1
avasopasem manganese
1
Valproic Acid
1
Thioctic Acid
1
Taxes
1
Receptors, Interleukin-6
1
Radiosurgery
1
RNA-Seq
1
Pemetrexed
1
Paclitaxel
1
Oxaliplatin
1
Multiparametric Magnetic Resonance Imaging
1
Leucovorin
1
Lenalidomide
1
Interleukin 1 Receptor Antagonist Protein
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Disease Progression
×
regorafenib
×
1 year
×
Clear all
NCT07514455
2026-04-07
RECOMEND
Asan Medical Center
Phase 2
Not yet recruiting
20 enrolled